← Back to Clinical Trials
Recruiting NCT06931093

NCT06931093 The Effectiveness of Group Guided Written Exposure Therapy for CPTSD Symptoms Among Adolescents

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06931093
Status Recruiting
Phase
Sponsor Peking University
Condition CPTSD, Compelx Post-traumatic Stress Disorder
Study Type INTERVENTIONAL
Enrollment 120 participants
Start Date 2025-04-10
Primary Completion 2026-03-10

Eligibility & Interventions

Sex All sexes
Min Age 10 Years
Max Age 18 Years
Study Type INTERVENTIONAL
Interventions
Group Guided Written Exposure Therapy for CPTSD (GWE-C)Supportive counselling

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 120 participants in total. It began in 2025-04-10 with a primary completion date of 2026-03-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to examine the effectiveness of group-delivered Guided Written Exposure Therapy for Complex Post-Traumatic Stress Disorder (GWE-C) among Chinese adolescents through a randomized controlled trial. A total of 120 participants will be recruited, with 60 randomized to the GWE-C group and 60 randomized to the supportive therapy (ST) group. The GWE-C intervention will consist of 7 to 10 group sessions. The primary outcome, assessed by the International Trauma Questionnaire (ITQ), will be measured at baseline, post-treatment, 1-month follow-up, and 3-month follow-up.

Eligibility Criteria

Inclusion Criteria: * Aged between 10 and 18 years; * Meet the diagnostic or subclinical criteria for Complex PTSD (C-PTSD), defined as the presence of at least one positive symptom in each of the PTSD symptom clusters, along with at least one positive symptom in each of the Disturbance in Self-Organization (DSO) symptom clusters; * Possess sufficient literacy and language skills to complete writing-based tasks; * Be able to understand the study procedures and complete the required assessments; * Provide written informed consent, with consent also obtained from their legal guardians. Exclusion Criteria: * Presence of a severe psychiatric disorder or neurodevelopmental disorder, such as schizophrenia, bipolar I disorder, autism spectrum disorder, intellectual disability, or other severe psychiatric conditions that would interfere with study participation; * Presence of a severe physical illness that would impair the ability to engage in the intervention; * Suicidal ideation within the past six months; * Ongoing exposure to traumatic events; * Currently receiving other trauma-focused psychological treatments.

Contact & Investigator

Central Contact

Yinyin Zang, Ph.D.

✉ yinyin.zang@pku.edu.cn

📞 00861062756953

Frequently Asked Questions

Who can join the NCT06931093 clinical trial?

This trial is open to participants of all sexes, aged 10 Years or older, up to 18 Years, studying CPTSD, Compelx Post-traumatic Stress Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06931093 currently recruiting?

Yes, NCT06931093 is actively recruiting participants. Contact the research team at yinyin.zang@pku.edu.cn for enrollment information.

Where is the NCT06931093 trial being conducted?

This trial is being conducted at Beijing, China.

Who is sponsoring the NCT06931093 clinical trial?

NCT06931093 is sponsored by Peking University. The trial plans to enroll 120 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology